

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								ATTY. DOCKET NO. PC25784A		SERIAL NO. 10/588,876			
								APPLICANT Justin Bryans					
								FILING DATE January 29, 2007		GROUP 1624			
<b>U.S. PATENT DOCUMENTS</b>													
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/DR/	US	3	8	4	0	5	9	7	10-8-74	Moore, et al	260	556F	
	US	4	2	3	3	2	9	9	11-11-80	Trummlitz, et al	424	246	
	US	4	8	8	5	3	6	7	12-5-89	Yoshikawa, et al.	546	216	
	US	4	8	8	1	4	6	0	11-21-89	Bannister, et al.	101	91	
	US	5	1	3	4	1	2	7	7-28-92	Rajewski, et al Equiv to <b>WO 94/02518</b>	514	58	
	US	5	3	4	4	9	9	1	9-6-94	Reitz, et al	568	34	
	US	5	3	8	0	7	3	8	1-10-95	Talley, et al Equiv to <b>WO 94/27980</b>	548	235	
	US	5	4	1	8	2	5	4	5-23-95	Huang, et al Equiv. to <b>WO 95/30656</b>	549	342	
	US	5	4	6	6	8	2	3	11-14-95	Talley, et al Equiv to <b>WO 95/15316</b>	546	279	
	US	5	4	7	4	9	9	5	12-12-95	Ducharme, et al Equiv to <b>WO 95/00501</b>	514	241	
	US	5	4	7	5	0	1	8	12-12-95	Bertenshaw, et al. Equiv to <b>WO 95/15315</b>	548	377.1	
	US	5	4	8	2	9	4	1	1-9-96	Terrett, et al. Equiv to <b>WO 93/12095</b>	544	284	
	US	5	4	8	6	5	3	4	1-23-96	Penning, et al. Equiv to <b>WO 96/03385</b>	548	375.1	
	US	5	5	9	1	7	4	2	1-7-97	Terrett, et al. Equiv to <b>WO 94/05661</b>	544	119	
	US	5	6	2	0	9	9	9	4-15-97	Barta, et al Equiv. to <b>WO 96/03387</b>	548	334.5	
	US	5	5	2	1	2	0	7	5-28-96	Graneto, Matthew J.	514	406	
	US	5	5	4	7	9	7	5	8-20-96	Graneto, et al Equiv. to <b>WO 96/609304</b>	548	359.5	
	US	5	5	7	6	3	2	2	11-19-96	Kimura, et al Equiv. to <b>WO 93/07124</b>	514	259	
	US	5	5	9	6	0	0	8	1-21-97	Lee, Len F. Equiv. to <b>WO 96/24585</b>	546	339	
V	US	5	6	1	6	6	0	1	4-1-97	Khanna, et al Equiv. to <b>WO 96/03388</b>	546	184	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							ATTY. DOCKET NO. PC25784A			SERIAL NO. 10/588,876		
							APPLICANT Justin Bryans		FILING DATE January 29, 2007			GROUP 1624
/DR/	US	5	6	3	3	2	7	2	5-27-97	Talley, et al Equiv. to <b>WO 96/25405</b>	514	378
	US	5	6	4	3	9	3	3	7-1-97	Graneto, et al. Equivalent <b>WO 96/38442</b>	514	378
	US	5	6	6	8	1	6	1	9-16-97	Collins, et al Equiv. to <b>WO 96/03392</b>	548	194
	US	5	6	7	0	5	1	0	9-23-97	Huang, et al Equiv. to <b>WO 95/30652</b>		
	US	5	7	3	1	3	4	3	3-24-98	Feng, et al. Equiv to <b>WO 96/25928</b>	514	450
	US	5	7	3	4	0	5	3	3-31-98	Terrett, et al. Equiv to <b>WO 94/00453</b>	544	277
	US	5	7	3	9	1	6	6	4-14-98	Li, et al Equiv. to <b>WO 96/16934</b>	514	716
	US	5	8	6	1	4	1	9	9-11-99	Fortin, et al Equiv. to <b>WO 98/03484</b>	514	356
	US	5	9	3	2	5	9	8	8-3-99	Talley, et al	514	341
	US	5	9	4	5	5	3	9	8-31-99	Haruta, et al	548	235
	US	5	9	6	8	9	7	4	10-19-99	Kargman, et al	514	461
	US	5	9	8	1	5	7	6	11-9-99	Belley, et al	514	473
	US	5	9	9	4	3	7	9	11-30-99	Bayly, et al	514	367
	US	5	9	9	4	3	8	1	11-30-99	Haruta, et al Equivalent to <b>JP9052882</b>	514	374
	US	6	0	0	1	8	4	3	12-14-99	Dube, et al	514	277
	US	6	0	0	2	0	1	4	12-14-99	Haruta, et al	548	235
	US	6	0	0	4	9	4	8	12-21-99	Blaschke, et al	514	155
	US	6	0	2	0	3	4	3	2-1-00	Belley, et al	514	309
	US	6	0	2	8	2	0	2	2-22-00	Connolly, et al	548	376.1
	US	6	0	3	4	2	5	6	3-7-00	Carter, et al	549	456
	US	6	0	4	0	3	2	0	3-21-00	Beers, et al	514	341
	US	6	0	4	0	4	5	0	3-21-00	Davies, et al	546	256
	US	6	0	4	3	2	5	2	3-28-00	Bombrun, et al	514	292
	US	6	0	4	6	2	1	7	4-4-00	Friesen, et al	514	347
	US	6	0	4	6	2	3	6	4-4-00	Hamanaka, et al	514	535
V	US	6	0	5	7	3	1	9	5-2-00	Black, et al	514	242

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							ATTY. DOCKET NO. PC25784A			SERIAL NO. 10/588,876		
							APPLICANT Justin Bryans					
							FILING DATE January 29, 2007			GROUP 1624		
/DR/	US	6	0	7	1	9	3	6	6-6-00	Dube, et al	514	334
	US	6	0	7	7	8	5	0	6-20-00	Carter, et al	514	311
	US	6	0	7	7	8	6	8	6-20-00	Cook, et al	514	560
	US	6	0	7	7	8	6	9	6-20-00	Sui, et al	514	615
	US	6	0	8	0	8	7	6	6-27-00	Dorziotis, et al	549	319
	US	6	0	8	3	9	6	9	7-4-00	Ferro, et al	514	403
	US	6	1	2	7	5	4	5	10-3-00	Pye, et al	546	286
	US	6	1	3	0	3	3	4	10-10-00	Pye, et al	546	286
	US	6	1	3	3	2	9	2	10-17-00	Wang, et al	514	336
	US	6	1	3	6	8	3	1	10-24-00	Aotsuka, et al	514	367
	US	6	1	4	0	5	1	5	10-31-00	Chen, et al	549	324
	US	6	1	4	3	7	4	6	11-7-00	Daugan, et al	514	249
	US	6	1	4	3	7	4	7	11-7-00	Freskos, et al	514	253.11
	US	6	1	5	3	7	8	7	11-28-00	Rossen, et al	560	187
	US	6	1	6	9	1	8	8	1-2-01	Belley, et al	549	330
	US	6	1	8	0	6	5	1	1-30-01	Nicolai, et al	514	336
	US	6	2	0	4	3	8	7	3-20-01	Davies, et al	546	315
	US	6	2	2	2	0	4	8	4-24-01	Black, et al.	549	60
	US	6	2	3	9	1	3	7	5-29-01	Karmali, et al	514	274
	US	6	2	3	9	1	7	3	5-29-01	Wang, et al	514	473
	US	6	2	5	1	9	0	4	6-26-01	Bunnage, et al Equivalent <b>WO 99/54333</b>	514	252.6
	US	6	2	7	1	2	5	3	8-7-01	Carter, et al	514	432
	US	6	2	7	4	5	9	0	8-14-01	Penning, et al Equivalent <b>WO 94/15932</b>	514	438
	US	6	2	9	7	2	8	2	10-2-01	Hartmann, et al	514	603
	US	6	3	0	0	3	6	3	10-9-01	Stevens, et al	514	415
	US	6	3	0	3	6	2	8	10-16-01	Nakao, et al	514	307
	US	6	3	0	6	8	9	0	10-23-01	Kalgutkar, et al	514	419
	US	6	3	0	7	0	4	7	10-23-01	Black, et al Equivalent <b>WO 00/24719</b>	544	240
▼	US	6	3	1	0	0	7	9	10-30-01	Okumura, et al	514	338

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							ATTY. DOCKET NO. PC25784A				SERIAL NO. 10/588,876		
							APPLICANT Justin Bryans				GROUP 1624		
/DR/	US	6	3	2	9	4	2	1	12-11-01	Prasit, et al	514	443	
		US	6	3	3	3	3	3	0	12-30-03	Bunnage, et al. Equivalent <b>WO 00/24745</b>	514	258
		US	6	3	4	0	6	9	4	1-22-02	Joo, et al	514	337
		US	6	3	5	9	1	8	2	3-19-02	Stamler, et al	568	949
		US	6	3	6	2	1	7	8	3-26-02	Shenke, et al. Equivalent <b>WO 99/24433</b>	544	184
		US	6	3	6	2	2	0	9	3-26-0	Haruta, et al	514	374
		US	6	3	6	9	2	7	5	4-9-02	Davies, et al	568	56
		US	6	3	7	6	5	1	9	4-23-02	Reddy, et al	514	341
		US	6	3	9	5	7	2	4	5-28-02	Judice, et al	514	183
		US	6	4	2	0	5	5	7	2-13-07	Storey, et al. Equivalent <b>WO 01/27113</b>	544	262
		US	6	4	4	2	9	9	9	8-13-02	Lu, et al. Equivalent <b>WO 96/38418</b>	548	375.1
		US	6	4	6	2	0	4	7	10-08-02	Bombrun, et al. Equivalent <b>WO 00/15639</b>	546	85
		US	6	5	8	3	1	4	7	06-24-03	Kyun, et al. Equivalent <b>WO 00/27848</b>	514	262.1
		US	6	7	2	3	7	1	9	2-4-04	Bunnage, et al. Equivalent <b>WO 98/49166</b>	514	241
		US	6	7	5	6	3	7	3	6-29-04	Allerton, et al. Equivalent <b>WO 01/27112</b>	546	276.1
		US	6	7	7	0	6	4	5	8-3-04	Newman, et al Equivalent <b>WO02/074774</b>	514	263.22
		US	6	7	8	4	1	8	5	8-31-04	Allerton, et al. Equivalent <b>WO 02/074312</b>	514	262.1
		US	6	7	9	4	3	8	7	9-21-04	Allerton, et al. Equivalent <b>WO 02/079203</b>	514	243
		US	6	8	2	5	1	9	7	11-30-04	Sawyer, et al. Equivalent <b>WO 02/00658</b>	544	343
↓		US	6	8	3	8	4	5	6	1-4-05	Gosmini, et al. Equivalent	546	64

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							ATTY. DOCKET NO. PC25784A			SERIAL NO. 10/588,876		
							APPLICANT Justin Bryans			GROUP 1624		
/DR/	US	6	8	5	8	6	2	0	2-22-05	WO 02/28859		
	US	6	8	7	2	7	2	1	3-29-05	Shultz, et al. Equivalent <b>WO 02/28865</b>	514	285
	US	6	8	7	8	7	1	1	4-12-05	Sawyer, et al. Equivalent <b>WO 01/94345</b>	514	250
	US	6	8	7	8	7	1	1	4-12-05	Shultz, et al. Equivalent <b>WO 02/36593</b>	544	9
	US	6	9	0	3	0	9	9	6-7-05	Shultz, et al. Equivalent <b>WO 02/00656</b>	544	343
	US	6	9	1	1	5	4	2	6-28-05	Shultz, et al. Equivalent <b>WO 02/00657</b>	544	343
	US	6	9	6	0	5	8	7	1-1-05	Shultz, et al. Equivalent <b>WO 02/38563</b>	544	345
	US	6	9	6	2	9	1	8	8-11-05	Shultz, et al. Equivalent <b>WO 02/8858</b>	544	343
	US	6	9	8	4	6	4	1	1-10-06	Gellibert, et al. Equivalent <b>WO 03/000691</b>	514	285
	US	7	0	2	2	8	5	6	4-4-06	SAWUER, et al. Equivalent <b>WO 02/064590</b>	514	292
	US	7	0	3	4	0	2	7	4-25-06	Shultz, et al. Equivalent <b>WO 02/10166</b>	544	343
↓	US	7	0	3	4	0	4	7	4-25-06	Junji, et al. Equivalent <b>WO 01/27113</b>	514	383

#### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
/DR/	EP	0	4	6	3	7	5	6	6-7-91	European	C07D	487/04
	EP	0	5	2	6	0	0	4	7-2-92	European	C07D	487/04
	EP	0	5	9	5	5	4	6	3-20-96	European	C07D	275/02
	EP	0	7	9	9	8	2	3	2-4-97	European	C07D	207/32
	EP	0	9	9	5	7	5	0	10-15-99	European	C07D	487/04
	EP	0	9	9	5	7	5	1	10-15-99	European	C07D	487/04
	EP	1	0	9	2	7	1	8	10-20-00	European	C07D	473/30
↓	EP	1	0	9	2	7	1	9	10-10-00	European	C07D	487/04

INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)						ATTY. DOCKET NO. PC25784A				SERIAL NO. 10/588,876					
						APPLICANT Justin Bryans				FILING DATE January 29, 2007			GROUP 1624		
						/DR/	EP	1	2	4	1	1	7	0	9-18-02
↓	EP	1	2	9	3	5	0	3	3-19-03	European	C07D	249/08			
↓	JP	0	0	0	6	3	3	6 3	8-12-98	International	C07D	249/08	yes		
↓	WO	9	3	0	6	1	0	4	4-1-93	International	C07D	487/04			
↓	WO	9	3	0	7	1	4	9	4-15-93	International	C07D	487/04			
↓	WO	9	5	1	9	9	7	8	7-27-95	International	C07D	471/14			
↓	WO	9	7	1	3	7	5	5	4-17-97	International	C07D	231/12			
↓	WO	9	8	4	7	8	9	0	10-29-98	International	C07D	311/58			
↓	WO	0	0	1	5	2	2	8	3-2-00	International	A61K	31/4985			
↓	WO	0	0	2	3	4	3	3	4-27-00	International	C07D	311/58			
↓	WO	0	0	3	5	2	9	8	6-22-00	International	A23G	3/30			
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)															
/DR/			Patent Application Publication No. US2003/153575, Pub. Date 8-14-03, Bomburn, et al., <b>Equivalent to WO 01/94347</b>												
↓			Patent Application Publication No. US2002/006443, Pub. Date 1-17-02, Babcock, et al., <b>Equivalent to WO 01/47495</b>												
↓			Patent Application Publication No. US2002/150616, Pub. Date 1-17-02, Vandecruys, et al., <b>Equivalent to WO 98/55148</b>												
↓			Patent Application Publication No. US2002/173502, Pub. Date 9-19-02, Allerton, et al., <b>Equivalent to WO 02/82597</b>												
↓			Patent Application Publication No. US2004/0067945, Pub. Date 4-8-04, Niewohner, et al., <b>Equivalent to WO 99/24433</b>												
↓			Carter, J., et al, <u>Expert Opinion on Therapeutic Patents</u> , "Recently reported inhibitors of cyclooxygenase-2", Vol. 8(1), pgs. 21-29 (1997)												
↓			Coco, A.S., <u>American Family Physician</u> , "Primary dysmenorrhea", Vol. 60, Pgs. 489-96 (1999).												
↓			Finnin, et al., <u>Journal Pharm Science</u> , 'Transdermal Penetration Enhancers': Applications, Limitations, and potential', Vol. 88 (10), 955-958, (1999)												
↓			Kakefuda, et al., <u>Bioorganic &amp; Medicinal Chemistry</u> , "Discovery of 4,5-Diphenyl-1,2,4-trizole Derivatives as a Novel Class of Selective antagonists for the Human V <sub>1A</sub> Receptor", Vol. 10, pg. 1905-1912, (2002)												
↓			Kakefuda, et al., <u>Journal of Medicinal Chemistry</u> , "Synthesis and Pharmacological evaluation of 5-4(4-Biphenyl)-3-methyl-4-phenyl-1,2,4-trizole Derivatives as a Novel Class of Selective antagonists for the Human V <sub>1A</sub> Receptor", Vol. 45, pg. 2589-2598, (2002)												
↓			Liang, et al., <u>Expert Opinion in Therapeutic Patents</u> , "Fast-dissolving intraoral drug deliver system", Vol. 11 (6), 981-986, (2001).												
↓			Rotella, et al., <u>Journal of Medicinal Chemistry</u> , "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction." Vol. 43(7), 1257-1263, (2000)												
↓			Schroeder, et al, <u>Pediatric Clinics of North America</u> , "J.S. Dysmenorrhea and pelvic pain in adolescents", Vol. 46, Pgs. 555-71 (1999).												
↓			Verma et al., <u>Pharmaceutical Technology On-line</u> , "Drug delivery technologies and future directions", Vol. 25(2), 1-14,(2001).												
EXAMINER /Deepak Rao/			DATE CONSIDERED				09/18/2008								